National PReCePT Programme: a before-and-after evaluation of the implementation of a national quality improvement programme to increase the uptake of magnesium sulfate in preterm deliveries

OBJECTIVE To evaluate the effectiveness and cost-effectiveness of the National PReCePT Programme (NPP) in increasing use of magnesium sulfate (MgSO4) in preterm births. DESIGN Before-and-after study. SETTING Maternity units (N=137) within NHS England and the Academic Health Science Network (AHSN) in 2018. PARTICIPANTS Babies born ≤30 weeks' gestation admitted to neonatal units in England. INTERVENTIONS The NPP was a quality improvement (QI) intervention including the PReCePT (Preventing Cerebral Palsy in Pre Term labour) QI toolkit and materials (preterm labour proforma, staff training presentations, parent leaflet, posters for the unit and learning log), regional AHSN-level support, and up to 90 hours funded backfill for a midwife 'champion' to lead implementation. MAIN OUTCOME MEASURES MgSO4 uptake post implementation was compared with pre-NPP implementation uptake. Implementation and lifetime costs were estimated. RESULTS Compared with pre-implementation estimates, the average MgSO4 uptake for babies born ≤30 weeks' gestation, in 137 maternity units in England, increased by 6.3 percentage points (95% CI 2.6 to 10.0 percentage points) to 83.1% post implementation, accounting for unit size, maternal, baby and maternity unit factors, time trends, and AHSN. Further adjustment for early/late initiation of NPP activities increased the estimate to 9.5 percentage points (95% CI 4.3 to 14.7 percentage points). From a societal and lifetime perspective, the health gains and cost savings associated with the NPP effectiveness generated a net monetary benefit of £866 per preterm baby and the probability of the NPP being cost-effective was greater than 95%. CONCLUSION This national QI programme was effective and cost-effective. National programmes delivered via coordinated regional clinical networks can accelerate uptake of evidence-based therapies in perinatal care.

[1]  W. Hollingworth,et al.  Evaluation of standard and enhanced quality improvement methods to increase the uptake of magnesium sulphate in pre-term deliveries for the prevention of neurodisability (PReCePT Study): a cluster randomized controlled trial , 2022, medRxiv.

[2]  Lee Kj,et al.  Framework for the Treatment And Reporting of Missing data in Observational Studies: The TARMOS framework. , 2021, Journal of clinical epidemiology.

[3]  S. Katikireddi,et al.  Conceptualising natural and quasi experiments in public health , 2020, BMC Medical Research Methodology.

[4]  K. Costeloe,et al.  The United Kingdom National Neonatal Research Database: A validation study , 2018, PloS one.

[5]  R. Carter,et al.  Economic evaluation and cost of interventions for cerebral palsy: a systematic review , 2018, Developmental medicine and child neurology.

[6]  A. Synnes,et al.  MAGnesium sulphate for fetal neuroprotection to prevent Cerebral Palsy (MAG-CP)—implementation of a national guideline in Canada , 2018, Implementation Science.

[7]  K. Luyt,et al.  Preventing cerebral palsy in preterm labour: a multiorganisational quality improvement approach to the adoption and spread of magnesium sulphate for neuroprotection , 2017, BMJ open quality.

[8]  S. Katikireddi,et al.  Natural Experiments: An Overview of Methods, Approaches, and Contributions to Public Health Intervention Research , 2017, Annual review of public health.

[9]  T. Weber,et al.  Use of magnesium sulfate before 32 weeks of gestation: a European population-based cohort study , 2017, BMJ Open.

[10]  A. Gasparrini,et al.  Interrupted time series regression for the evaluation of public health interventions: a tutorial , 2016, International journal of epidemiology.

[11]  A. Smith-Collins,et al.  Protecting the premature brain: current evidence-based strategies for minimising perinatal brain injury in preterm infants , 2016, Archives of Disease in Childhood: Fetal and Neonatal Edition.

[12]  C. Gale,et al.  The UK National Neonatal Research Database: using neonatal data for research, quality improvement and more , 2016, Archives of Disease in Childhood: Education & Practice Edition.

[13]  P. Middleton,et al.  Barriers and enablers to implementing antenatal magnesium sulphate for fetal neuroprotection guidelines: a study using the theoretical domains framework , 2015, BMC Pregnancy and Childbirth.

[14]  C. Mitton,et al.  Magnesium sulphate for fetal neuroprotection: a cost-effectiveness analysis , 2013, BMC Health Services Research.

[15]  L. Doyle,et al.  Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus ( Review ) , 2022 .